Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATR positive |
| Therapy | Berzosertib + Cisplatin |
| Indication/Tumor Type | lung cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATR positive | lung cancer | sensitive | Berzosertib + Cisplatin | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Berzosertib (VX-970) sensitized patient-derived lung cancer cells to Platinol (cisplatin) in culture and in patient-derived xenograft (PDX) models (PMID: 25010037). | 25010037 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25010037) | Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. | Full reference... |